Related Experiment Videos
SP220K is a novel matrix serine proteinase
1Laboratoire de Biochimie, Faculté de Médecine, Nice, France.
International Journal of Cancer
|July 3, 1998
Summary
A novel serine proteinase (SP220K) from kidney cancer exhibits gelatinase activity, degrading fibronectin and type I collagen. Its unique inhibition profile suggests it
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Matrix proteinases are crucial for extracellular matrix remodeling, impacting cancer invasion and metastasis.
- A novel tetrameric serine proteinase, SP220K, was previously purified from human kidney clear cell carcinoma plasma membranes.
Purpose of the Study:
- To characterize the enzymatic activity and substrate specificity of the novel serine proteinase SP220K.
- To investigate the potential role of SP220K in matrix degradation.
Main Methods:
- Assessing gelatinase activity in solution and via zymography.
- Hydrolysis assays using fibronectin, type I collagen, laminin, and type IV collagen.
- Enzyme inhibition studies using a panel of proteinase inhibitors.
Main Results:
- SP220K demonstrated gelatinase activity optimally between pH 7.5 and 9.0.
- SP220K specifically hydrolyzed fibronectin and type I collagen, releasing the N-terminal heparin-binding domain of fibronectin.
- SP220K displayed a unique inhibition profile distinct from other known serine proteinases.
Conclusions:
- SP220K is a novel matrix proteinase with specific activity against fibronectin and type I collagen.
- The findings suggest SP220K's potential role in cancer-related matrix remodeling.
- SP220K represents a new target for understanding cancer invasion and metastasis.